NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Both false. It was a partial halt, not for safety, and apparently it was the placebo arm that was halted because too many patients had crossed over and randomizing patients to a placebo arm that was no longer valid, would be unethical. You can’t tell the company or the patients to avoid spoiling the results.

And the fact is no, the placebo arm MOSTLY crossed over as recurrent patients and we know recurrent patients had an incredibly great survival response as well as newly diagnosed patients.

The measure you claim it failed on is invalid. It is not a valid measure correlated to the survival of patients. PFS is ONLY valid as an early predictor for survival, and then you have a Phase 4 to confirm it. Most of the other, already approved, early, based on PFS alone, immunotherapies actually failed to prove survival in many cases. Yet the FDA allowed most to stay approved for other benefits.

In this case you have even more quality of life benefits, you have a clearly applicable idea of how this will likely work, method of action, with other immunotherapy drugs and not least of which, you actually have the first substantial improvement in OS for many patients, some seemingly cured, for a systemic treatment in many, years, probably actually ever.

Your claims are part of the formalist rejection of progress because it will endanger their profits in treating very ill people. There are no doubt massive profits that will be lost for the ameliorative products if drugs like DCVax-L come to market and in combination do prove to ultimately cure a substantial number of patients without the horrors of treatment that cost so much and bankrupt families.